Krystal Biotech, Inc. KRYS PP&E Sale Proceeds
PP&E Sale Proceeds at other companies
Other financials
Where this comes from
Reported directly by Krystal Biotech, Inc. in its filing.
Tagged under the XBRL concept us-gaap:ProceedsFromSaleOfPropertyPlantAndEquipment.
The official record: Krystal Biotech, Inc.’s 10-Q, filed May 4, 2026, on SEC EDGAR. View the filing →
Ask your AI about Krystal Biotech, Inc.'s pp&e sale proceeds.
Connect your AI assistant and compare it to peers, right in your chat.
Connect your AI
Claude
Questions, answered.
- What is Krystal Biotech, Inc.'s PP&E sale proceeds?
- Krystal Biotech, Inc. (KRYS) reported PP&E sale proceeds of $0 in Q1 2026.
- How has Krystal Biotech, Inc.'s PP&E sale proceeds changed year-over-year?
- Krystal Biotech, Inc.'s PP&E sale proceeds decreased by 100.0% year-over-year, from $435K to $0.
- What does PP&E sale proceeds mean?
- Cash received from selling physical assets like property or machinery.
- How do you interpret PP&E sale proceeds?
- An increase suggests asset liquidation or optimization, while a zero value is typical for growing biotech firms focusing on capacity expansion.
- How does PP&E sale proceeds compare across companies?
- Commonly low or zero for R&D-focused biotech firms that rarely divest core infrastructure.